Form 4: UroGen Pharma Executive Sells Shares
Insider Transaction (Form 4)
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd., sold 871 shares of common stock on September 7, 2026 for $42.92 per share.
Summary
- Option exercise/conversion: acquired 1,667 Ordinary Shares on September 7, 2026; holds 60,753 after (Direct).
- Open-market sale: disposed of 871 Ordinary Shares at $42.92 ($37,383) on September 8, 2026; holds 59,882 after (Direct).
- Option exercise/conversion: disposed of 1,667 Restricted Stock Units on September 7, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $37,383 of stock on the open market.
Insider Transactions
Mark Schoenberg — Officer (Chief Medical Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-07 | Option exercise/conversion | Ordinary Shares | 1,667 | — | — | 60,753 |
| 2026-09-08 | Open-market sale | Ordinary Shares | 871 | $43 | $37.4K | 59,882 |
| 2026-09-07 | Option exercise/conversion | Restricted Stock Units | 1,667 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-07 | Option exercise/conversion (1,667 shares) |
| 2026-09-08 | Open-market sale (871 shares) |
| 2026-09-07 | Option exercise/conversion (1,667 shares) |
Keywords
insider transaction, Form 4, URGN, UroGen Pharma Ltd., bearish, Mark Schoenberg
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.